



**BENCH TO  
BEDSIDE**  
URO-ONCOLOGY  
GU CANCER TRIAD



**Register now!**

**SCIENTIFIC PROGRAMME COMMITTEE**



Peter  
BLACK  
Canada



Peter  
HAMMERER  
Germany



Pilar  
LAGUNA  
Turkey



Rafael  
SANCHEZ-SALAS  
France

**December 13–14, 2019 in Berlin, Germany**

[www.siu-urology.org](http://www.siu-urology.org)



#B2BGUCancerTriad

Day 1  
Friday, December 13, 2019



TIME	SESSION TITLE	INVITED SPEAKERS
0800	Welcome and Introduction	Peter Black, Canada and Pilar Laguna, Turkey
<b>Clinical Development of Immunotherapy for Bladder Cancer</b>		
0815–0835	Immunotherapy in Metastatic Urothelial Carcinoma	Petros Grivas, United States
<b>Where to next?</b>		
0835–0850	Perioperative Immunotherapy for MIBC	Andrea Necchi, Italy
0850–0905	Combining Trimodal Therapy with Checkpoint Blockade	Wassim Kassouf, Canada
0905–0920	Immunotherapy and Evolving Therapies in NMIBC	Peter Black
0920–0945	Discussion / Q&A	Moderator: Peter Black Petros Grivas, United States Wassim Kassouf, Canada Andrea Necchi, Italy
0945–1010	Health Break	
<b>Clinical Development of Immunotherapy for Kidney Cancer</b>		
1010–1030	Immunotherapy in Metastatic RCC	Christian Kollmannsberger, Canada
1030–1115	Multimodal Therapy of mRCC: Case-based Panel (to include discussion of cytoreductive Nx and SABR or surgery of mets)	Moderator: Michael Staehler, Germany Axel Bex, The Netherlands Dirk Böhmer, Germany Christian Kollmannsberger, Canada
1115–1135	Role of Perioperative IO and Targeted Therapy in High-risk RCC	Viktor Grünwald, Germany
<b>Adverse Events/Toxicities</b>		
1135–1220	Case-based Discussions on Adverse Events / Toxicities Associated with Immunotherapy	Moderator: Kilian Gust, Austria Christian Kollmannsberger, Canada Pablo Maroto Rey, Spain Andrea Necchi, Italy Srikala Sridhar, Canada
1220–1320	Lunch Break	
<b>Biomarkers of Response to Therapy</b>		
1320–1405	Developing Biomarkers for Clinical Utilization in Advanced Bladder Cancer: Panel Discussion	Moderator: Andrea Necchi, Italy Petros Grivas, United States Gopa Iyer, United States Tilman Todenhöfer, Germany
1405–1435	The Microbiome in Tumor Immunology	Lisa Derosa, France
1435–1450	Health Break	
<b>The Pipeline</b>		
1450–1510	FGFR Inhibitors in Urothelial Carcinoma	Gopa Iyer, United States
1510–1530	Antibody Drug Conjugates in Urothelial Carcinoma	Srikala Sridhar, Canada
1530–1550	State of the Art: CAR-T-Cell Therapy	
1550–1610	Discussion	Moderators: Peter Black and Pilar Laguna Gopa Iyer, United States Srikala Sridhar, Canada
1610–1630	Concluding Remarks	Peter Black and Pilar Laguna

Day 2  
Saturday, December 14, 2019



TIME	SESSION TITLE	INVITED SPEAKERS
<b>Part I. Prostate Cancer I</b>		
0800–0810	Welcome Message	Peter Hammerer, Germany and Rafael Sanchez-Salas, France
0810–0830	Who and When: Germ-line DNA Testing in Prostate Cancer Patients	Thorsten Schlomm, Germany
<b>Management of High Risk Non-metastatic Prostate Cancer</b>		
0830–0845	What is important for the surgeon?	Rafael Sanchez-Salas
0845–0905	What is important for the radiotherapist?	Alberto Bossi, France
0905–0925	Discussion (with Q&A)	Moderator: Peter Hammerer Alberto Bossi, France Rafael Sanchez-Salas Thorsten Schlomm, Germany
<b>Managing Oligometastatic Prostate Cancer</b>		
0925–0945	Treatment of the Primary	Prasanna Sooriakumaran, United Kingdom
0945–1005	Definitive Treatment of the Mets	Dirk Böhmer, Germany
1005–1025	Systemic Therapy	Noel Clarke, United Kingdom
1025–1110	Case-based Panel Discussion (with Q&A)	Moderator: Rafael Sanchez-Salas Dirk Böhmer, Germany Karim Fizazi, France Peter Hammerer, Germany Noel Clarke, United Kingdom Prasanna Sooriakumaran, United Kingdom
1110–1130	Health Break	
<b>Part II. Prostate Cancer II</b>		
1130–1155	Managing Biochemical Recurrence after Definitive Local Therapy: Case-based Panel Discussion (with Q&A)	Moderator: Peter Hammerer Alberto Bossi, France Axel Heidenreich, Germany Pablo Maroto Rey, Spain Derya Tilki, Germany Rafael Sanchez-Salas, France
1155–1215	Sequencing of Systemic Therapy for mCSPC & mCRPC	Karim Fizazi, France
1215–1235	Liquid Biopsy to Support Clinical Decision-making	Klaus Pantel, Germany
1235–1255	nmCRPC: Treatment Options in an Endangered Disease State	Antonio Alcaraz, Spain
1255–1345	Lunch Break	
<b>mCRPC Systemic Therapy Pipeline</b>		
1345–1405	Immunotherapy	Pablo Maroto Rey, Spain
1405–1425	PARP Inhibitors	Noel Clarke, United Kingdom
1425–1445	PSMA-Theranostics	Frederik Giesel, Germany
1445–1500	Concluding Remarks	Peter Hammerer and Rafael Sanchez-Salas



**BENCH OF  
BEDSIDE**  
URO-ONCOLOGY  
GU CANCER TRIAD



Meeting Venue  
Berlin Marriott Hotel  
Inge-Beisheim-Platz 1  
10785 Berlin, Germany

## Registration Rates

Urologists  
Medical Oncologists  
Radiation Oncologists  
Other Specialists

**€150**

Residents  
Trainees  
Fellows  
Nurses

**€65**

This programme is made possible by unrestricted educational grants provided by Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd and Ferring Pharmaceuticals.